ArticleAntimicrobial agents and chemotherapy2013
Efficacy of proveblue (methylene blue) in an experimental cerebral malaria murine model.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Methylene blue treatment of fatal cerebral malaria and identification of potential blood biomarkers.Nature communications · 2025Article
- Methylene Blue-Based Combination Therapy with Amodiaquine Prevents Severe Malaria in an Experimental Rodent Model.Pharmaceutics · 2022Article
- In Vitro Evaluation of the Antiviral Activity of Methylene Blue Alone or in Combination against SARS-CoV-2.Journal of clinical medicine · 2021Article
- Absence of Association between Methylene Blue Reduced Susceptibility and Polymorphisms in 12 Genes Involved in Antimalarial Drug Resistance in AfricanPharmaceuticals (Basel, Switzerland) · 2021Article
- Methylene blue inhibits replication of SARS-CoV-2 in vitro.International journal of antimicrobial agents · 2020Article
- Inhibitory action of phenothiazinium dyes against Neospora caninum.Scientific reports · 2020Article
- Nucleoside-lipid-based nanocarriers for methylene blue delivery: potential application as anti-malarial drug.RSC advances · 2019Article
- Malaria, tuberculosis and HIV: what's new? Contribution of the Institut Hospitalo-Universitaire Méditerranée Infection in updated data.New microbes and new infections · 2018Article
- Contribution of the French army health service in support of expertise and research in infectiology in Africa.New microbes and new infections · 2018Article
- Differential activity of methylene blue against erythrocytic and hepatic stages of Plasmodium.Malaria journal · 2018Article
- Inhibiting the NLRP3 Inflammasome With Methylene Blue as Treatment Adjunct in Myelodysplasia.Frontiers in oncology · 2018Article
- Methylene blue and its analogues as antidepressant compounds.Metabolic brain disease · 2017Review
- Review
- Plasmodium falciparum susceptibility to standard and potential anti-malarial drugs in Dakar, Senegal, during the 2013-2014 malaria season.Malaria journal · 2015Article
- Methylene blue inhibits the asexual development of vivax malaria parasites from a region of increasing chloroquine resistance.The Journal of antimicrobial chemotherapy · 2015Article
- Methylene blue promotes quiescence of rat neural progenitor cells.Frontiers in cellular neuroscience · 2014Article
- Gametocytocidal screen identifies novel chemical classes with Plasmodium falciparum transmission blocking activity.PloS one · 2014Article
- Dose responses of proveblue methylene blue in an experimental murine cerebral malaria model.Antimicrobial agents and chemotherapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although 100% of untreated mice infected with Plasmodium berghei died with specific signs of cerebral malaria and 100% of mice treated with 3 mg/kg dihydroartemisinin, the active metabolite of artesunate, which is used as the first-line treatment for severe malaria, also died but showed no specific signs of cerebral malaria, 78% of mice treated with 10 mg/kg Proveblue (methylene blue) and 78% of mice treated with a combination of 3 mg dihydroartemisinin and 10 mg/kg Proveblue survived and showed no specific signs of cerebral malaria or detectable parasites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.